Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Poly ICLC (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 10 Feb 2017 Planned End Date changed from 1 Aug 2016 to 1 Apr 2017.